Why do bondholders and leveraged speculators have to be enriched, instead of providing fiscal relief to the unemployed and small businesses? That’s the question.
Politicians raved about it. Experts were cautious: “an interesting first signal,” many questions remain. Even Pfizer said, “as the study continues, the final vaccine efficacy percentage may vary.”
